Compounds · Muscle, bone & joint · Muscle growth and tissue repair enhancement
IGF-1 LR3
Long R3 IGF-1, IGF-1 Long Arg3, Recombinant Human IGF-1 Long R3
Synthetic IGF-1 analog engineered for longer half-life and reduced binding to IGF-binding proteins, making it far more potent than natural IGF-1. Used in research on cell growth and differentiation, but widely misused in bodybuilding for muscle building.
20–40 mcg daily
Research score 40/100. Reference only, not a prescription.
- Muscle Growth
- Recovery Enhancement
- Angiogenesis
- Growth Hormone Release
- Healing
- US status
- Research Chemical
- Approval
- Research Chemical Only
- Evidence
- No FDA approval. Limited human clinical data (mostly anecdotal/gray market).
- Research score
- 40 / 100
- Indication
- Research Only - No Medical Indication
- Origin
- Australia
- Source category
- Muscles & Joints
- Status group
- Research chemical
Mechanism
An arginine substitution and 13-amino-acid N-terminal extension cut IGF-binding-protein attachment and extend circulation time; acting through the IGF-1 receptor, it strongly drives PI3K/Akt/mTOR and MAPK/ERK signaling, boosting protein synthesis, amino acid uptake, and satellite-cell activity in muscle.
Safety file
High risk of hypoglycemia; potential for organ enlargement (acromegaly), insulin resistance, and cancer promotion. Not approved for human therapeutic use.
- Hypoglycemia
- Joint pain
- Water retention
- Possible growth of existing tissues including unwanted growth
- Headaches
Important: IGF-1 peptides are insulin-like and can drop your blood sugar. Eat a meal with protein and carbs shortly after injecting, watch for low blood sugar signs, and do not inject within 2 hours of bedtime (overnight hypoglycaemia risk).
Reconstitution
| Vial | 1 mL water | 2 mL water |
|---|---|---|
| 1 mg | 1 mg/mL | 0.5 mg/mL |
As with IGF-1 DES, bac water is the common practical diluent for a vial used within its window. A low-pH diluent is sometimes preferred for longer storage.
- Use bacteriostatic water as the diluent.
- Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
- Swirl gently to mix, then leave it to dissolve. Do not shake.
- Give it a few minutes. The finished solution should be clear and colourless.
Protocol
Route: Subcutaneous or intramuscular
Standard protocol (subcutaneous or intramuscular)
- Beginners: 0.02 mg to 0.04 mg (20 to 40 mcg) per day, once daily, ideally post-workout
- Start at the low end and assess tolerance for the first 1 to 2 weeks
- Do not exceed 0.05 mg/day (50 mcg) without real experience
Dosing detail
- Beginner dose is 0.02 mg to 0.04 mg (20 to 40 mcg) once daily. Intermediate 0.05 to 0.08 mg (50 to 80 mcg).
- Long-acting, so once daily is enough. Post-workout or morning is the usual timing.
- Eat after dosing and avoid late-night injections to prevent overnight low blood sugar.
- Cycle 4 to 6 weeks on, equal time off, to keep receptors responsive.
Duration
- Run 4 to 6 weeks, then an equal time off: it is long-acting (20 to 30 hour half-life) and the receptors downregulate with continuous use.
Notes
- A long-acting IGF-1 variant, systemic rather than purely local.
- Watch for low blood sugar signs.
- Inject subcutaneously and rotate sites.
Storage and handling
- Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
- Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
- Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
- If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.